Home LiteratureArticle Details
PMID: 23458891 Published · ppublish English Journal Article Review

NAFLD in Asia--as common and important as in the West.

Nature reviews. Gastroenterology & hepatology ·Vol. 10 ·No. 5 ·2013-05-00 ·Pages 307-18

Farrell GC, Wong VW, Chitturi S

Abstract

NAFLD--regarded as a consequence of the modern sedentary, food-abundant lifestyle prevalent in the West--was recorded in Japan nearly 50 years ago and its changing epidemiology during the past three decades is well-documented. NAFLD, and its pathologically more severe form NASH, occur in genetically susceptible people who are over-nourished. Asian people are particularly susceptible, partly owing to body composition differences in fat and muscle. Community prevalence ranges between 20% (China), 27% (Hong Kong), and 15-45% (South Asia, South-East Asia, Korea, Japan and Taiwan). This Review presents emerging data on genetic polymorphisms that predispose Asian people to NAFLD, NASH and cirrhosis, and discusses the clinical and pathological outcomes of these disorders. NAFLD is unlikely to be less severe in Asians than in other populations, but the associated obesity and diabetes pandemics have occurred more recently in Asia than in Europe and the USA, and occur with reduced degrees of adiposity. Cases of cryptogenic cirrhosis and hepatocellular carcinoma have also been attributed to NAFLD. Public health efforts to curb over-nutrition and insulin resistance are needed to prevent and/or reverse NAFLD, as well as its adverse health outcomes of type 2 diabetes, cardiovascular events, cirrhosis and liver cancer.

MeSH Terms
Asia/epidemiology Fatty Liver/epidemiology,genetics Genetic Predisposition to Disease Genotype Humans Non-alcoholic Fatty Liver Disease Prevalence Risk Factors
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Farrell Geoffrey C
ANU Medical School, Australian National University and Gastroenterology and Hepatology Unit, The Canberra Hospital, Yamba Drive, Garran, ACT 2605, Australia. [email protected]
Wong Vincent Wai-Sun
Chitturi Shiv
References (163)
163 references, click to expand
  1. A position statement on NAFLD/NASH based on the EASL 2009 special conference.
    J Hepatol. 2010 Aug;53(2):372-84 PMID: 20494470
  2. Ethnicity and nonalcoholic fatty liver disease.
    Hepatology. 2012 Mar;55(3):769-80 PMID: 21987488
  3. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.
    Ann Intern Med. 2005 Nov 15;143(10):722-8 PMID: 16287793
  4. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease.
    Gastroenterology. 2010 Nov;139(5):1567-76, 1576.e1-6 PMID: 20708005
  5. Nonalcoholic fatty liver disease is associated with coronary artery calcification.
    Hepatology. 2012 Aug;56(2):605-13 PMID: 22271511
  6. A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio.
    J Gastroenterol Hepatol. 2008 Sep;23(9):1415-8 PMID: 18853997
  7. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
    J Gastroenterol Hepatol. 2007 Jun;22(6):794-800 PMID: 17498218
  8. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease.
    J Hepatol. 2008 May;48(5):829-34 PMID: 18321606
  9. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.
    J Gastroenterol. 2011 Jan;46(1):101-7 PMID: 20658156
  10. Dietary habits and nutrient intake in non-alcoholic steatohepatitis.
    Nutrition. 2007 Jan;23(1):46-52 PMID: 17140767
  11. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people.
    Liver Int. 2008 Mar;28(3):385-92 PMID: 17999673
  12. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome.
    Hepatology. 2002 Feb;35(2):373-9 PMID: 11826411
  13. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders.
    J Gastroenterol Hepatol. 2007 Jul;22(7):1086-91 PMID: 17608855
  14. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
    Mayo Clin Proc. 1980 Jul;55(7):434-8 PMID: 7382552
  15. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
    Gastroenterology. 2011 Jan;140(1):124-31 PMID: 20858492
  16. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis.
    J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):116-21 PMID: 16706822
  17. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease.
    Hepatology. 2008 Jun;47(6):1947-54 PMID: 18454505
  18. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.
    PLoS Genet. 2011 Mar;7(3):e1001324 PMID: 21423719
  19. Variant in PNPLA3 is associated with alcoholic liver disease.
    Nat Genet. 2010 Jan;42(1):21-3 PMID: 19946271
  20. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.
    Am J Gastroenterol. 2012 Jan;107(1):46-52 PMID: 22085817
  21. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.
    J Hepatol. 2012 Dec;57(6):1276-82 PMID: 22878467
  22. Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease.
    South Med J. 2008 Sep;101(9):900-5 PMID: 18708987
  23. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease.
    Clin Gastroenterol Hepatol. 2006 Sep;4(9):1154-61 PMID: 16904946
  24. Prevalence of non-alcoholic fatty liver in a hypercholesterolemic population of northwestern peninsular Malaysia.
    Southeast Asian J Trop Med Public Health. 2010 Jul;41(4):936-42 PMID: 21073069
  25. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study.
    Aliment Pharmacol Ther. 2001 Oct;15(10):1667-72 PMID: 11564008
  26. TNF-alpha as therapeutic target in NASH: tried, but not yet proven.
    J Gastroenterol Hepatol. 2007 May;22(5):613-4 PMID: 17444846
  27. Significant non-alcoholic fatty liver disease is found in non-diabetic, pre-obese Chinese in Singapore.
    Singapore Med J. 2007 Aug;48(8):752-7 PMID: 17657385
  28. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.
    Diabetologia. 2012 Apr;55(4):885-904 PMID: 22278337
  29. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.
    Hepatology. 2010 Sep;52(3):913-24 PMID: 20648476
  30. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area.
    Digestion. 2011;84 Suppl 1:17-22 PMID: 22156481
  31. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?
    World J Gastroenterol. 2010 Feb 21;16(7):800-3 PMID: 20143458
  32. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.
    Lancet. 2006 Nov 11;368(9548):1673-9 PMID: 17098085
  33. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary.
    J Gastroenterol Hepatol. 2007 Jun;22(6):775-7 PMID: 17565629
  34. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?
    Hepatol Res. 2012 Jan;42(1):1-14 PMID: 21917086
  35. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.
    Lancet. 2010 Dec 4;376(9756):1916-22 PMID: 21109302
  36. Fatty liver and the metabolic syndrome among Shanghai adults.
    J Gastroenterol Hepatol. 2005 Dec;20(12):1825-32 PMID: 16336439
  37. Epidemiology of non-alcoholic fatty liver disease in China.
    J Hepatol. 2009 Jan;50(1):204-10 PMID: 19014878
  38. Non-alcoholic fatty liver disease in a rural, physically active, low income population in Sri Lanka.
    BMC Res Notes. 2011 Nov 24;4:513 PMID: 22115060
  39. A Val227Ala polymorphism in the peroxisome proliferator activated receptor alpha (PPARalpha) gene is associated with variations in serum lipid levels.
    J Med Genet. 2002 Mar;39(3):189-91 PMID: 11897821
  40. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population.
    Clin Gastroenterol Hepatol. 2012 Jun;10(6):646-50 PMID: 22245962
  41. Clues from the carotids: an appraisal of cardiovascular disease risk in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2009 Aug;24(8):1315-7 PMID: 19702897
  42. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease.
    Gastroenterology. 2009 Aug;137(2):532-40 PMID: 19409898
  43. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France.
    J Hepatol. 2012 Aug;57(2):376-83 PMID: 22521354
  44. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.
    Hepatology. 2011 Oct;54(4):1208-16 PMID: 21688282
  45. Relationship between uric acid and hepatic steatosis among Koreans.
    Diabetes Metab. 2009 Dec;35(6):447-51 PMID: 19879789
  46. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan.
    J Diabetes Complications. 2010 Sep-Oct;24(5):345-53 PMID: 20656522
  47. Insulin resistance at diagnosis in Japanese children with type 2 diabetes mellitus.
    Pediatr Int. 2012 Aug;54(4):516-9 PMID: 22360541
  48. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies.
    Br J Cancer. 2007 Oct 8;97(7):1005-8 PMID: 17700568
  49. How should we manage patients with non-alcoholic fatty liver disease in 2007?
    J Gastroenterol Hepatol. 2007 Jun;22(6):801-8 PMID: 17565632
  50. Severe obesity is associated with novel single nucleotide polymorphisms of the ESR1 and PPARgamma locus in Han Chinese.
    Am J Clin Nutr. 2009 Aug;90(2):255-62 PMID: 19491387
  51. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease.
    Hepatology. 2005 Feb;41(2):372-9 PMID: 15723436
  52. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
    Hepatology. 2010 Jun;51(6):1972-8 PMID: 20209604
  53. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B.
    Gut. 2009 Jan;58(1):111-7 PMID: 18832522
  54. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.
    Hepatology. 2010 Jul;52(1):79-104 PMID: 20578268
  55. Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones.
    Metabolism. 2005 Apr;54(4):529-32 PMID: 15798962
  56. Cholesteryl ester transfer protein gene polymorphisms increase the risk of fatty liver in females independent of adiposity.
    J Gastroenterol Hepatol. 2012 Sep;27(9):1520-7 PMID: 22414273
  57. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease.
    Aliment Pharmacol Ther. 2006 Oct 15;24(8):1215-22 PMID: 17014580
  58. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study.
    J Gastroenterol Hepatol. 2012 Jan;27(1):91-5 PMID: 21679251
  59. A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease.
    Hum Genet. 2012 Jul;131(7):1145-52 PMID: 22258181
  60. APOC3 and PNPLA3 in non-alcoholic fatty liver disease: need to clear the air.
    J Gastroenterol Hepatol. 2012 May;27(5):848-51 PMID: 22369128
  61. Hepatitis B virus infection and fatty liver in the general population.
    J Hepatol. 2012 Mar;56(3):533-40 PMID: 22027575
  62. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?
    J Gastroenterol Hepatol. 2007 Jun;22(6):788-93 PMID: 17565631
  63. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.
    J Hepatol. 2005 Jan;42(1):132-8 PMID: 15629518
  64. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?
    J Gastroenterol Hepatol. 2003 Feb;18(2):124-38 PMID: 12542595
  65. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis.
    J Clin Gastroenterol. 2008 Apr;42(4):413-8 PMID: 18277895
  66. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population.
    J Gastroenterol Hepatol. 2009 Jul;24(7):1284-8 PMID: 19476560
  67. Risk factors for liver steatosis in obese children and adolescents.
    Pediatr Neonatol. 2010 Jun;51(3):149-54 PMID: 20675238
  68. Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts.
    Hepatology. 2011 Jun;53(6):1792-4 PMID: 21557278
  69. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection.
    J Gastroenterol Hepatol. 2008 Sep;23(9):1419-25 PMID: 18853998
  70. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese.
    J Gastroenterol Hepatol. 2012 Oct;27(10):1555-60 PMID: 22741595
  71. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
    Gastroenterology. 2012 Apr;142(4):711-725.e6 PMID: 22326434
  72. Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus.
    J Gastroenterol Hepatol. 2011 Mar;26(3):517-22 PMID: 21054523
  73. Statin use and reduced cancer-related mortality.
    N Engl J Med. 2012 Nov 8;367(19):1792-802 PMID: 23134381
  74. Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study.
    Int J Mol Med. 2008 Oct;22(4):521-7 PMID: 18813860
  75. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
    Liver Int. 2011 Oct;31(9):1326-31 PMID: 21745282
  76. Genetic determinants of alcoholic liver disease.
    Gut. 2012 Jan;61(1):150-9 PMID: 22110053
  77. Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2011 Mar;26(3):510-6 PMID: 21155882
  78. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults.
    J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):138-43 PMID: 16706825
  79. Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease.
    Indian J Gastroenterol. 2005 Nov-Dec;24(6):251-5 PMID: 16424622
  80. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.
    Hepatology. 2011 Aug;54(2):463-71 PMID: 21538440
  81. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan.
    J Gastroenterol Hepatol. 2007 Sep;22(9):1482-9 PMID: 17716352
  82. Potential for statins in the chemoprevention and management of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2012 Nov;27(11):1654-64 PMID: 22849701
  83. Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease.
    Hum Pathol. 2012 Jun;43(6):790-800 PMID: 22036053
  84. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.
    J Hepatol. 2012 Jan;56(1):255-66 PMID: 21723839
  85. Epidemic obesity and type 2 diabetes in Asia.
    Lancet. 2006 Nov 11;368(9548):1681-8 PMID: 17098087
  86. [CLINICAL ASPECTS OF FATTY LIVER].
    Chiryo. 1964 Jan;46:1-12 PMID: 14110964
  87. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.
    BMC Gastroenterol. 2012 Aug 16;12:111 PMID: 22898488
  88. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes.
    Diabetes Care. 2012 Apr;35(4):717-22 PMID: 22338098
  89. Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2009 Aug;24(8):1411-6 PMID: 19702910
  90. Non-alcoholic fatty liver disease in Malaysia: a demographic, anthropometric, metabolic and histological study.
    J Dig Dis. 2007 Feb;8(1):58-64 PMID: 17261137
  91. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
    N Engl J Med. 2010 May 6;362(18):1675-85 PMID: 20427778
  92. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease.
    Hepatology. 2010 Jun;51(6):1961-71 PMID: 20301112
  93. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men.
    Diabetes Care. 2007 Nov;30(11):2940-4 PMID: 17666460
  94. Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground.
    J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:163-72 PMID: 21199528
  95. Histological features of non-alcoholic fatty liver disease: what is important?
    J Gastroenterol Hepatol. 2012 Jan;27(1):5-7 PMID: 22188024
  96. Diabetes and hepatocellular cancer risk: not only a matter of hyperglycemia.
    Hepatology. 2012 Apr;55(4):1298-300 PMID: 22461078
  97. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease.
    N Engl J Med. 2010 Mar 25;362(12):1082-9 PMID: 20335584
  98. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men.
    Gut. 2009 Oct;58(10):1419-25 PMID: 19505882
  99. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
    J Gastroenterol Hepatol. 2007 May;22(5):634-8 PMID: 17444848
  100. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.
    Gut. 2010 Jul;59(7):969-74 PMID: 20581244
  101. Does non-alcoholic fatty liver disease predispose patients to type 2 diabetes in the absence of obesity?
    J Gastroenterol Hepatol. 2010 Feb;25(2):223-5 PMID: 20136984
  102. Nonalcoholic fatty liver disease in Asia: a story of growth.
    J Gastroenterol Hepatol. 2013 Jan;28(1):18-23 PMID: 23094755
  103. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population.
    Hepatology. 2009 Jul;50(1):175-84 PMID: 19441103
  104. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.
    Hepatology. 2011 Nov;54(5):1610-9 PMID: 21748765
  105. Liver cholesterol: is it playing possum in NASH?
    Am J Physiol Gastrointest Liver Physiol. 2012 Jul;303(1):G9-11 PMID: 22556144
  106. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.
    Nat Genet. 2008 Dec;40(12):1461-5 PMID: 18820647
  107. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.
    Gastroenterology. 2001 Jul;121(1):91-100 PMID: 11438497
  108. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.
    Hepatology. 2010 Jan;51(1):121-9 PMID: 19827166
  109. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome.
    Nat Rev Gastroenterol Hepatol. 2010 May;7(5):251-64 PMID: 20368739
  110. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease.
    Am J Gastroenterol. 2011 Mar;106(3):460-8; quiz 469 PMID: 21206486
  111. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis.
    J Hepatol. 2009 Aug;51(2):371-9 PMID: 19501928
  112. Interactions of obesity and glucose-stimulated insulin secretion in familial hypertriglyceridemia.
    Diabetes. 1978 Jun;27(6):682-93 PMID: 658614
  113. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease.
    Hepatology. 2010 May;51(5):1593-602 PMID: 20222092
  114. The natural history of nonalcoholic fatty liver disease: a population-based cohort study.
    Gastroenterology. 2005 Jul;129(1):113-21 PMID: 16012941
  115. Significant correlations between severe fatty liver and risk factors for metabolic syndrome.
    J Gastroenterol Hepatol. 2007 Dec;22(12):2118-23 PMID: 18031368
  116. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability.
    Aliment Pharmacol Ther. 2007 Sep 15;26(6):821-30 PMID: 17767466
  117. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup.
    J Gastroenterol Hepatol. 2010 Feb;25(2):352-6 PMID: 19817963
  118. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines.
    J Gastroenterol Hepatol. 2007 Jun;22(6):778-87 PMID: 17565630
  119. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps.
    J Gastroenterol Hepatol. 2010 Mar;25(3):562-7 PMID: 20074156
  120. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men.
    J Gastroenterol Hepatol. 2004 Jun;19(6):694-8 PMID: 15151626
  121. The association between nonalcoholic fatty liver disease, metabolic syndrome and arterial stiffness in nondiabetic, nonhypertensive individuals.
    Cardiology. 2012;123(1):54-61 PMID: 22986520
  122. Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies.
    Arch Intern Med. 2006 Dec 11-25;166(22):2437-45 PMID: 17159008
  123. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
    J Gastroenterol Hepatol. 2010 Apr;25(4):672-90 PMID: 20492324
  124. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology. 2012 Jun;55(6):2005-23 PMID: 22488764
  125. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Dig Liver Dis. 2012 Jun;44(6):492-6 PMID: 22265683
  126. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.
    Gastroenterology. 2002 Jul;123(1):134-40 PMID: 12105842
  127. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus.
    J Gastroenterol Hepatol. 2013 Jan;28(1):142-7 PMID: 22989165
  128. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography.
    Gut. 2012 Mar;61(3):409-15 PMID: 21846782
  129. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2010 Apr;51(4):1209-17 PMID: 20373368
  130. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).
    J Hepatol. 2012 Aug;57(2):384-91 PMID: 22521357
  131. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese.
    PLoS One. 2012;7(6):e38322 PMID: 22719876
  132. Long-term follow-up of patients with NAFLD and elevated liver enzymes.
    Hepatology. 2006 Oct;44(4):865-73 PMID: 17006923
  133. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.
    Hepatology. 2012 Sep;56(3):943-51 PMID: 22505194
  134. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.
    Am J Hum Genet. 2008 Oct;83(4):520-8 PMID: 18940312
  135. The utility of radiological imaging in nonalcoholic fatty liver disease.
    Gastroenterology. 2002 Sep;123(3):745-50 PMID: 12198701
  136. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life.
    J Hepatol. 2010 Aug;53(2):335-8 PMID: 20546964
  137. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis.
    Prog Lipid Res. 2013 Jan;52(1):175-91 PMID: 23206728
  138. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome.
    Diabetes Res Clin Pract. 2009 Apr;84(1):84-91 PMID: 19168251
  139. Molecular dynamics simulation of PNPLA3 I148M polymorphism reveals reduced substrate access to the catalytic cavity.
    Proteins. 2013 Mar;81(3):406-14 PMID: 23042597
  140. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
    Hepatology. 2007 Apr;45(4):846-54 PMID: 17393509
  141. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.
    Hepatology. 2011 Jun;53(6):1874-82 PMID: 21360720
  142. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.
    Gastroenterology. 2008 Jul;135(1):111-21 PMID: 18505690
  143. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.
    N Engl J Med. 2003 Apr 24;348(17):1625-38 PMID: 12711737
  144. Protective effect of alcohol consumption for fatty liver but not metabolic syndrome.
    World J Gastroenterol. 2012 Jan 14;18(2):156-67 PMID: 22253522
  145. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.
    Hepatology. 2010 May;51(5):1820-32 PMID: 20432259
  146. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population.
    J Gastroenterol Hepatol. 2011 Feb;26(2):300-5 PMID: 21261720
  147. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis.
    J Clin Invest. 2012 Nov;122(11):4130-44 PMID: 23023705
  148. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors.
    J Gastroenterol Hepatol. 2012 Aug;27(8):1341-7 PMID: 22554085
  149. Hepatocellular carcinoma in nonalcoholic fatty liver cirrhosis and alcoholic cirrhosis: risk factor analysis in liver transplant recipients.
    Eur J Gastroenterol Hepatol. 2012 Jul;24(7):840-8 PMID: 22495397
  150. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study.
    J Hepatol. 2009 May;50(5):1029-34 PMID: 19299029
  151. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children.
    World J Gastroenterol. 2008 Mar 14;14(10):1598-602 PMID: 18330955
  152. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial.
    JAMA. 2002 May 15;287(19):2559-62 PMID: 12020337
  153. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement.
    Obes Surg. 2006 Oct;16(10):1278-86 PMID: 17059735
  154. Histopathology of nonalcoholic fatty liver disease.
    World J Gastroenterol. 2010 Nov 14;16(42):5286-96 PMID: 21072891
  155. NASH and cryptogenic cirrhosis: a histological analysis.
    Ann Hepatol. 2009 Oct-Dec;8(4):346-52 PMID: 20009134
  156. Association of raised liver transaminases with physical inactivity, increased waist-hip ratio, and other metabolic morbidities in severely obese children.
    J Pediatr Gastroenterol Nutr. 2008 Aug;47(2):172-8 PMID: 18664869
  157. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.
    Am J Gastroenterol. 2012 Feb;107(2):253-61 PMID: 22008893
  158. Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus.
    Hepatogastroenterology. 2011 Nov-Dec;58(112):2103-5 PMID: 22024083
  159. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease.
    Gut. 2011 Dec;60(12):1721-7 PMID: 21602530
  160. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.
    Hepatology. 2010 Feb;51(2):454-62 PMID: 20101745
  161. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis.
    Gut. 2011 Jun;60(6):829-36 PMID: 21339204
  162. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?
    J Gastroenterol Hepatol. 2004 Apr;19(4):368-74 PMID: 15012772
  163. Parental history of type 2 diabetes mellitus, metabolic syndrome, and cardiometabolic risk factors in Asian Indian adolescents.
    Metabolism. 2009 Mar;58(3):344-50 PMID: 19217449
Article Info
Journal
Nature reviews. Gastroenterology & hepatology
Abbr.
Nat Rev Gastroenterol Hepatol
ISSN
1759-5053
DOI
10.1038/nrgastro.2013.34
Email
[email protected]
Published
2013-05-00
Epub
2013-00-05
Pages
307-18
Language
English
Region
England
NLM ID
101500079
Subset
IM
External Links
PubMed source DOI: 10.1038/nrgastro.2013.34 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2